通过分子动力学模拟,解开β2上腺体受体中偏差激动的结构基础
Wojciech Plazinski1,2, Aneta Archala1, Krzysztof Jozwiak1
1Department of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Proteins
|November 16, 2024
概括
不同的甲氧纳甲醇 (MNFen) 立体异构体在β2-上腺素受体 (β2-AR) 中引起明显的结构变化,揭示了偏向性激动的分子基础. 这些发现揭示了药物开发的选择性途径激活.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 计算生物学 计算生物学
背景情况:
- G蛋白结合受体 (GPCRs) 通过多种信号通路调解细胞反应.
- 偏差激进主义描述了不同的连接体如何可以选择性地激活特定的下游通路 (例如,Gs,Gi,arrestin).
- 了解偏见激进主义的结构基础对于开发有针对性的治疗方法至关重要.
研究的目的:
- 为了研究在β2-上腺素受体 (β2-AR) 的联结体诱导偏向激动的基础结构机制.
- 阐明甲氧纳甲醇 (MNFen) 的立体异构体如何诱导差异信号.
- 为了确定关键的受体残留物和相互作用,负责偏差信号结果.
主要方法:
- 用 (R,R) -MNFen及其立体异构体对β2-AR复合物的原子分子动力学 (MD) 模拟.
- 粗粒模拟用于确认来自原子模拟的发现.
- 分析受体-连接体相互作用和细胞内区域的结构变化.
主要成果:
- 对于每个MNFen立体同位素,观察到明显的结合腔相互作用.
- (R,R) -MNFen复合体表现出类似于Gs和β-arrestin兼容构造的细胞内动力学.
- 像Trp313和Lys305-Asp192桥梁这样的关键残留物在调解立体同位素特异性结构反应方面发挥了关键作用.
结论:
- 连接体立体化学决定了通过特定的结构重组在β2-AR的偏向性激励作用.
- 这项研究提供了关于MNFen立体异构体如何差异性参与β2-AR的原子层次见解.
- 这些发现有助于合理设计具有改善治疗选择性的偏向激动剂.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Adrenergic Receptors: β Subtype
1.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.5K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
813
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
813
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K


